Furthermore, this study showed that the altered subcellular localization of KLF4 could affect the resistance to cetuximab, suggesting a way to block the localized expression of KLF4 in the nucleus to improve the efficacy of cetuximab in the treatment of nasopharyngeal carcinoma as well as head and neck tumors. Here, KLF4 is linked to head and neck neoplasm.